LETSIMMUN
Lymphocyte Engineering for Therapeutic Synthetic Immunity
Adoptive T cell therapy has advanced to become a distinguished and rapidly evolving translational research field in modern medicine (June et al., 2015). This collaborative research center (CRC) transregio (TRR) LETSIMMUN is setting out to become a hot spot for cutting-edge basic and translation research in Lymphocyte Engineering in Germany, and aspires to deliver novel concepts and cell products for clinical development that provide Therapeutic Synthetic Immunity for patients.
Veranstaltungen
Projekte
Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper. Mehr
People
Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper. Mehr
Downloads
Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper. Mehr
The DFG has approved another funding period for LETSimmun! We are delighted to be able to continue our successful projects and to welcome new outstanding scientists and projects to our network.
Joint publication by Matthias Feige and Kathrin Schumann: Human interleukin-12α and EBI3 are cytokines with anti-inflammatory functions
Videos
Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper. Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper.Pellentesque pulvinar ac lacus vel egestas. Nunc facilisis libero ornare nulla ullamcorper. Mehr
Kontakt
Sed ut perspiciatis unde omnis iste natus voluptatem.
Trogerstr.30
81675 München
+4989 4140 6887
m.nauerth@tum.de